Psychiatry Research: Neuroimaging
Volume 172, Issue 3 , Pages 242-250 , 30 June 2009

Changes after behavior therapy among responsive and nonresponsive patients with obsessive-compulsive disorder

  • Tomoaki Yamanishi

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • ,
  • Shutaro Nakaaki

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Tel.: +81 52 853 8271; fax: +81 52 852 0837.
    • ,
  • Ichiro M. Omori

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • ,
  • Nobuhiko Hashimoto

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • ,
  • Yoshihiro Shinagawa

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • ,
  • Jin Hongo

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • ,
  • Masaru Horikoshi

      Affiliations

    • Department of Comprehensive Human Sciences, University of Tsukuba Graduate School, Tsukuba City, Japan
    • ,
  • Junko Tohyama

      Affiliations

    • Department of Radiology, TOYOTA -kai Medical Corporation Kariya, Toyota General Hospital, Nagoya City, Japan
    • ,
  • Tatsuo Akechi

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan
    • ,
  • Tsutomu Soma

      Affiliations

    • Clinical Application Technology Group, Fujifilm RI Pharma Company Limited, Tokyo, Japan
    • Department of Medical Physics and Engineering, Division of Medical Technology and Science, Graduate School of Medicine, Osaka University, Osaka, Japan
    • ,
  • Tetsuya Iidaka

      Affiliations

    • Department of Psychiatry, Nagoya University, Graduate School of Medicine, Nagoya City, Japan
    • ,
  • Toshi A. Furukawa

      Affiliations

    • Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya City, Japan

Received 17 November 2007 ,Revised 19 May 2008 ,Accepted 4 July 2008.

References 

  1. Abramowitz JS, Foa EB, Franklin ME. Exposure and ritual prevention for obsessive–compulsive disorder: effects of intensive versus twice-weekly sessions. Journal of Consulting and Clinical Psychology. 2003;71:394–398
  2. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, et al. Pathophysiology of obsessive–compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Progress in Neurobiology. 2004;72:195–221
  3. Baxter LR. Neuroimaging studies of human anxiety disorders: cutting paths of knowledge through the field of neurotic phenomena. In:  Bloom F,  Kupfer D editor. Neuropsychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995;p. 1287–1299
  4. Baxter LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive–compulsive disorder. Archives of General Psychiatry. 1992;49:681–689
  5. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry. 1999;174:297–303
  6. Bonne O, Louzoun Y, Aharon I, Krausz Y, Karger H, Lerer B, et al. Cerebral blood flow in depressed patients: a methodological comparison of statistical parametric mapping and region of interest analyses. Psychiatry Research. 2003;122:49–57
  7. Beck AT, Steer RA, Brown GK. BDI-II Manual. The Psychological Corporation: San Antonio, TX. 1996;
  8. Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, et al. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Research: Neuroimaging. 1998;84:1–6
  9. Cavedini P, Riboldi G, D'Annucci A, Belotti P, Cisima M, Bellodi L. Decision-making heterogeneity in obsessive–compulsive disorder: ventromedial prefrontal cortex function predicts different treatment outcomes. Neuropsychologia. 2002;40:205–211
  10. Chang LT. A method for attenuation correction in radionuclide computedtomography. IEEE transaction on nuclear.. Science. 1978;25:638–643
  11. De Haan E, van Oppen P, van Balkom AJ, Spinhoven P, Hoogduin KA, Van Dyck R. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatrica Scandinavica. 1997;96:354–361
  12. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. NeuroImage. 2002;15:870–878
  13. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, et al. Modulation of cortical–limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry. 2004;61:34–41
  14. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale–Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry. 1989;46:1006–1011
  15. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale–Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry. 1989;46:1012–1016
  16. Hendler T, Goshen E, Tzila Zwas S, Sasson Y, Gal G, Zohar J. Brain reactivity to specific symptom provocation indicates prospective therapeutic outcome in OCD. Psychiatry Research: Neuroimaging. 2003;124:87–103
  17. Iikura Y. Treatment Guide for Obsessive-Compulsive Disorder. Nihei-Sha. Osaka; 1999;
  18. Jenike MA. Drug treatment of obsessive compulsive disorders. In:  Jenike MA,  Baer L,  Minichiello WE editor. Obsessive-Compulsive Disorder: Practical Management. New York: Mosby; 1998;p. 469–554
  19. Kampman M, Keijsers GP, Hoogduin CA, Verbraak MJ. Addition of cognitive-behaviour therapy for obsessive–compulsive disorder patients non-responding to fluoxetine. Acta Psychiatrica Scandinavica. 2002;106:314–319
  20. Kang DH, Kwon JS, Kim JJ, Youn T, Park HJ, Kim MS, et al. Brain glucose metabolic changes associated with neuropsychological improvements after 4 months of treatment in patients with obsessive–compulsive disorder. Acta Psychiatrica Scandinavica. 2003;107:291–297
  21. Lucey JV, Costa DC, Blanes T, Busatto GF, Pilowsky LS, Takei N, et al. Regional cerebral blood flow in obsessive–compulsive disordered patients at rest. Differential correlates with obsessive–compulsive and anxious-avoidant dimensions. British Journal of Psychiatry. 1995;167:629–634
  22. Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive–compulsive disorder. American Journal of Psychiatry. 1999;156:1409–1416
  23. Mataix-Cols D, Wooderson S, Lawrence N, Brammer MJ, Speckens A, Phillips ML. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive–compulsive disorder. Archives of General Psychiatry. 2004;61:564–576
  24. Matsuda H, Ohnishi T, Asada T, Li ZJ, Kanetaka H, Imabayashi E, et al. Correction for partial-volume effects on brain perfusion SPECT in healthy men. Journal of Nuclear Medicine. 2003;44:1243–1252
  25. Matsuda H, Mizumura S, Soma T, Takemura N. Conversion of brain SPECT images between different collimators and reconstruction processes for analysis using statistical parametric mapping. Nuclear Medicine Communications. 2004;25:67–74
  26. Milad MR, Quinn BT, Pitman RK, Orr SP, Fischl B, Rauch SL. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:10706–10711
  27. Milad MR, Rauch SL. The orbitofrontal cortex and anxiety disorders. In:  Zald DH,  Rauch SL editor. The Orbitofrontal Cortex. New York: Oxford University Press; 2006;p. 523–543
  28. Nakatani E, Nakgawa A, Ohara Y, Goto S, Uozumi N, Iwakiri M, et al. Effects of behavior therapy on regional cerebral blood flow in obsessive–compulsive disorder. Psychiatry Research: Neuroimaging. 2003;124:113–120
  29. Nakatani E, Nakagawa A, Nakao T, Yoshizato C, Nabeyama M, Kudo A, et al. A randomized controlled trial of Japanese patients with obsessive–compulsive disorder—effectiveness of behavior therapy and fluvoxamine. Psychotherapy and Psychosomatics. 2005;74:269–276
  30. Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, et al. A functional MRI comparison of patients with obsessive–compulsive disorder and normal controls during a Chinese character Stroop task. Psychiatry Research: Neuroimaging. 2005;139:101–114
  31. Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, et al. Brain activation of patients with obsessive–compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biological Psychiatry. 2005;57:901–910
  32. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive–compulsive disorder: a multicenter double-blind trial. Journal of Clinical Psychiatry. 2006;67:15–22
  33. Ohnishi T. SPM. In:  Matsuda H,  Asada T editor. Imaging Diagnosis for Dementia. Osaka: Nagai Shoten; 2004;p. 73–89
  34. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive–compulsive disorder. Journal of clinical Psychiatry. 2004;65(Suppl 14):6–10
  35. Phelps EA, Delgado MR, Nearing KI, LeDoux JE. Extinction learning in humans: role of the amygdala and vmPFC. Neuron. 2004;43:897–905
  36. Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology. 2002;27:782–791
  37. Remijnse PL, Nielen MM, van Balkom AJ, Cath DC, van Oppen P, Uylings HB, et al. Reduced orbitofrontal–striatal activity on a reversal learning task in obsessive–compulsive disorder. Archives of General Psychiatry. 2006;63:1225–1236
  38. Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive–compulsive disorder. Neuropsychopharmacology. 1999;21:683–693
  39. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, et al. Differential cerebral metabolic changes with paroxetine treatment of obsessive–compulsive disorder vs major depression. Archives of General Psychiatry. 2002;59:250–261
  40. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR. Differential brain metabolic predictors of response to paroxetine in obsessive–compulsive disorder versus major depression. American Journal of Psychiatry. 2003;160:522–532
  41. Saxena, S., Gorbis, E., O'Neill, J., Baker, S.K., Mandelkern, M.A., Maidment, K.M., Chang, S., Salamon, N., Brody, A.L., Schwartz, J.M., London, E.D., 2009. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive–compulsive disorder. Molecular Psychiatry 14, 197–205.
  42. Schwartz JM, Stoessel PW, Baxter LR, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive–compulsive disorder. Archives of General Psychiatry. 1996;53:109–113
  43. Schwartz JM. Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive–compulsive disorder. An evolving perspective on brain and behaviour. British Journal of Psychiatry (Suppl). 1998;38–44
  44. Spielberger CD, Gorsuch R, Lushene R. Manual for the State-Trait Anxiety Inventory. Consulting Psychologist Press, Palo Alto, CA. 1970;
  45. Takeuchi Y, Tohyama J, Katano H, Mase M, Kanai H, Yamada K. Identification of motor activation brain perfusion SPECT with brain easy analysis tools. Nagoya Medical Journal. 2005;47:57–66
  46. Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive–compulsive disorder: a wait-list-controlled open trial. Journal of Clinical Psychiatry. 2004;65:922–931
  47. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive–compulsive disorder: a signal detection analysis of the Yale–Brown Obsessive Compulsive Scale. Journal of Clinical Psychiatry. 2005;66:1549–1557
  48. Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive–compulsive disorder. Psychiatry Research: Neuroimaging. 2004;132:69–79

PII: S0925-4927(08)00097-8

doi: 10.1016/j.pscychresns.2008.07.004

Psychiatry Research: Neuroimaging
Volume 172, Issue 3 , Pages 242-250 , 30 June 2009

Article Tools

* Image Usage & Resolution